Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

Share:
Related PFE
It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.

In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”

Pfizer closed on Thursday at $31.12.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Get Benzinga's Newsletters